Schabath et al
Supplementary Figure



Supplementary Fig. 1. Impact of *STK11* and *TP53* mutations on *KRAS* mutation-associated gene expression in TCGA dataset. (a-c) Boxplots indicating *KRAS* mutation-associated (RAS de novo) signature activity (PC1) within each gene group (a) *KRAS*, (b) *STK11*, and (c) *TP53*. T-test was used to determine significance in difference in signature activity between mut and wt groups indicated. Sample size (n), mean and standard deviation (std) is indicated on top of each figure. (d) Boxplots and (e) pairwise comparison plots indicating RAS de novo signature activity in indicated co-occurring and exclusive mutations in *KRAS* and *STK11*. ANOVA was used to determine overall significant difference in RAS de novo signature activity among indicated groups and Tukey honest significant difference method was used to adjust for p value for pairwise comparison. (f) Boxplots and (g) pairwise comparison plots indicating RAS de novo signature activity in indicated co-occurring and exclusive mutations in *KRAS* and *TP53*. Additional methodology is provided in Supplemental Information.